Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Identification and characterization of two novel oncogenic mTOR mutations.

Murugan AK, Liu R, Xing M.

Oncogene. 2019 Mar 27. doi: 10.1038/s41388-019-0787-5. [Epub ahead of print]

PMID:
30918329
2.

Entering an Era of Precision Management of Thyroid Cancer.

Xing M.

Endocrinol Metab Clin North Am. 2019 Mar;48(1):xvii-xviii. doi: 10.1016/j.ecl.2018.12.001. No abstract available.

PMID:
30717915
3.

Genetic-guided Risk Assessment and Management of Thyroid Cancer.

Xing M.

Endocrinol Metab Clin North Am. 2019 Mar;48(1):109-124. doi: 10.1016/j.ecl.2018.11.007. Review.

PMID:
30717896
4.

BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer.

Wang F, Zhao S, Shen X, Zhu G, Liu R, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Wang Y, Xing M.

J Clin Oncol. 2018 Sep 20;36(27):2787-2795. doi: 10.1200/JCO.2018.78.5097. Epub 2018 Aug 2.

5.

Reply to M. Melo et al.

Shen X, Xing M.

J Clin Oncol. 2018 May 10;36(14):1457-1458. doi: 10.1200/JCO.2018.78.2169. Epub 2018 Mar 23. No abstract available.

PMID:
29570420
6.

Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer.

Liu R, Zhang T, Zhu G, Xing M.

Nat Commun. 2018 Feb 8;9(1):579. doi: 10.1038/s41467-018-03033-1.

7.

Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer.

Shen X, Zhu G, Liu R, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Xing M.

J Clin Oncol. 2018 Feb 10;36(5):438-445. doi: 10.1200/JCO.2017.74.5497. Epub 2017 Dec 14.

8.

BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.

Huang Y, Qu S, Zhu G, Wang F, Liu R, Shen X, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Xing M.

J Natl Cancer Inst. 2018 Apr 1;110(4):362-370. doi: 10.1093/jnci/djx227.

PMID:
29165667
9.

87th Annual Meeting of the American Thyroid Association October 18-22, 2017, Victoria, British Columbia, Canada.

Leung AM, Xing M.

Thyroid. 2017 Oct;27(10):1213-1214. doi: 10.1089/thy.2017.29049.aml. No abstract available.

PMID:
28961086
10.

When Somatic Mutations Are Associated With a Higher Aggressive Behavior-Reply.

Liu R, Xing M.

JAMA Oncol. 2017 Oct 1;3(10):1428-1429. doi: 10.1001/jamaoncol.2017.1513. No abstract available.

PMID:
28617916
11.

The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.

Wang F, Yu X, Shen X, Zhu G, Huang Y, Liu R, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Wang Y, Liu S, Zhao J, Zhao S, Xing M.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3241-3250. doi: 10.1210/jc.2017-00277.

12.

Identification and characterization of novel PAX8 mutations in Congenital Hypothyroidism(CH) in a Chinese population.

Liu S, Wang X, Zou H, Ge Y, Wang F, Wang Y, Yan S, Xia H, Xing M.

Oncotarget. 2017 Jan 31;8(5):8707-8716. doi: 10.18632/oncotarget.14419.

13.

A six-genotype genetic prognostic model for papillary thyroid cancer.

Shen X, Liu R, Xing M.

Endocr Relat Cancer. 2017 Jan;24(1):41-52. Epub 2016 Nov 14.

14.

Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.

Zhang T, Shen X, Liu R, Zhu G, Bishop J, Xing M.

Oncotarget. 2017 Jan 3;8(1):900-914. doi: 10.18632/oncotarget.13400.

15.

Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality.

Liu R, Bishop J, Zhu G, Zhang T, Ladenson PW, Xing M.

JAMA Oncol. 2017 Feb 1;3(2):202-208. doi: 10.1001/jamaoncol.2016.3288.

PMID:
27581851
16.

Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data.

Chai YJ, Yi JW, Jee HG, Kim YA, Kim JH, Xing M, Lee KE.

PLoS One. 2016 Jul 13;11(7):e0159235. doi: 10.1371/journal.pone.0159235. eCollection 2016.

17.

Response.

Zhang T, Shen X, Xing M.

J Natl Cancer Inst. 2016 May 6;108(8). pii: djw124. doi: 10.1093/jnci/djw124. Print 2016 Aug. No abstract available.

18.

BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.

Jin L, Chen E, Dong S, Cai Y, Zhang X, Zhou Y, Zeng R, Yang F, Pan C, Liu Y, Wu W, Xing M, Zhang X, Wang O.

Oncotarget. 2016 Apr 5;7(14):18346-55. doi: 10.18632/oncotarget.7811.

19.

Recent incidences and differential trends of thyroid cancer in the USA.

Mao Y, Xing M.

Endocr Relat Cancer. 2016 Apr;23(4):313-22. doi: 10.1530/ERC-15-0445. Epub 2016 Feb 25.

20.

The sonic hedgehog signaling pathway stimulates anaplastic thyroid cancer cell motility and invasiveness by activating Akt and c-Met.

Williamson AJ, Doscas ME, Ye J, Heiden KB, Xing M, Li Y, Prinz RA, Xu X.

Oncotarget. 2016 Mar 1;7(9):10472-85. doi: 10.18632/oncotarget.7228.

21.

Molecular Aberrance in Papillary Thyroid Microcarcinoma Bearing High Aggressiveness: Identifying a "Tibetan Mastiff Dog" From Puppies.

Li D, Gao M, Li X, Xing M.

J Cell Biochem. 2016 Jul;117(7):1491-6. doi: 10.1002/jcb.25506. Epub 2016 Feb 11. Review.

PMID:
26841328
22.

HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.

Zhang T, Xing M.

J Natl Cancer Inst. 2016 Feb 1;108(6):djv415. doi: 10.1093/jnci/djv415. Print 2016 Jun.

23.
24.

Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.

Cheng W, Liu R, Zhu G, Wang H, Xing M.

J Clin Endocrinol Metab. 2016 Mar;101(3):962-71. doi: 10.1210/jc.2015-3433. Epub 2016 Jan 11.

25.

TERT promoter mutations in thyroid cancer.

Liu R, Xing M.

Endocr Relat Cancer. 2016 Mar;23(3):R143-55. doi: 10.1530/ERC-15-0533. Epub 2016 Jan 5. Review.

26.

Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.

Yin DT, Xu J, Lei M, Li H, Wang Y, Liu Z, Zhou Y, Xing M.

Oncotarget. 2016 Feb 2;7(5):5830-41. doi: 10.18632/oncotarget.6709.

27.

Uncommon TERT Promoter Mutations in Pediatric Thyroid Cancer.

Alzahrani AS, Qasem E, Murugan AK, Al-Hindi HN, AlKhafaji D, Almohanna M, Xing M, Alhomaidah D, AlSwailem M.

Thyroid. 2016 Feb;26(2):235-41. doi: 10.1089/thy.2015.0510. Epub 2016 Jan 21.

PMID:
26711586
28.

Prediction of cervical lymph node metastasis in patients with papillary thyroid cancer using combined conventional ultrasound, strain elastography, and acoustic radiation force impulse (ARFI) elastography.

Xu JM, Xu XH, Xu HX, Zhang YF, Guo LH, Liu LN, Liu C, Bo XW, Qu S, Xing M, Li XL.

Eur Radiol. 2016 Aug;26(8):2611-22. doi: 10.1007/s00330-015-4088-2. Epub 2015 Nov 11.

PMID:
26560715
29.

Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.

Shi X, Liu R, Basolo F, Giannini R, Shen X, Teng D, Guan H, Shan Z, Teng W, Musholt TJ, Al-Kuraya K, Fugazzola L, Colombo C, Kebebew E, Jarzab B, Czarniecka A, Bendlova B, Sykorova V, Sobrinho-Simões M, Soares P, Shong YK, Kim TY, Cheng S, Asa SL, Viola D, Elisei R, Yip L, Mian C, Vianello F, Wang Y, Zhao S, Oler G, Cerutti JM, Puxeddu E, Qu S, Wei Q, Xu H, O'Neill CJ, Sywak MS, Clifton-Bligh R, Lam AK, Riesco-Eizaguirre G, Santisteban P, Yu H, Tallini G, Holt EH, Vasko V, Xing M.

J Clin Endocrinol Metab. 2016 Jan;101(1):264-74. doi: 10.1210/jc.2015-2917. Epub 2015 Nov 3.

30.

REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer.

Liu D, Shen X, Zhu G, Xing M.

Oncotarget. 2015 Nov 17;6(36):39211-24. doi: 10.18632/oncotarget.5391.

31.

Quantitative Shear Wave Velocity Measurement on Acoustic Radiation Force Impulse Elastography for Differential Diagnosis between Benign and Malignant Thyroid Nodules: A Meta-analysis.

Liu BJ, Li DD, Xu HX, Guo LH, Zhang YF, Xu JM, Liu C, Liu LN, Li XL, Xu XH, Qu S, Xing M.

Ultrasound Med Biol. 2015 Dec;41(12):3035-43. doi: 10.1016/j.ultrasmedbio.2015.08.003. Epub 2015 Sep 12. Review.

PMID:
26371402
32.

TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.

Qasem E, Murugan AK, Al-Hindi H, Xing M, Almohanna M, Alswailem M, Alzahrani AS.

Endocr Relat Cancer. 2015 Dec;22(6):901-8. doi: 10.1530/ERC-15-0396. Epub 2015 Sep 9.

PMID:
26354077
33.

Simultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancer.

Tsumagari K, Abd Elmageed ZY, Sholl AB, Friedlander P, Abdraboh M, Xing M, Boulares AH, Kandil E.

Cancer Lett. 2015 Nov 1;368(1):46-53. doi: 10.1016/j.canlet.2015.07.011. Epub 2015 Jul 21.

34.

Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis.

McLeod DS, Jonklaas J, Brierley JD, Ain KB, Cooper DS, Fein HG, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Xing M, Litofsky DR, Maxon HR, Sherman SI.

Thyroid. 2015 Oct;25(10):1097-105. doi: 10.1089/thy.2015.0148. Epub 2015 Aug 24.

35.

Reply to C. Bal et al.

Xing M.

J Clin Oncol. 2015 Aug 1;33(22):2483-4. doi: 10.1200/JCO.2015.61.4867. Epub 2015 Jun 29. No abstract available.

PMID:
26124484
36.

BRAF Mutation and Thyroid Cancer Recurrence.

Xing M.

J Clin Oncol. 2015 Aug 1;33(22):2482-3. doi: 10.1200/JCO.2015.61.4016. Epub 2015 Jun 29. No abstract available.

PMID:
26124474
37.

Acoustic Radiation Force Impulse Elastography in the Diagnosis of Thyroid Nodules: Useful or Not Useful?

Zhang YF, Xu HX, Xu JM, Liu C, Guo LH, Liu LN, Zhang J, Xu XH, Qu S, Xing M.

Ultrasound Med Biol. 2015 Oct;41(10):2581-93. doi: 10.1016/j.ultrasmedbio.2015.05.018. Epub 2015 Jun 26.

PMID:
26119458
38.

Reply to M. Melo et al.

Xing M.

J Clin Oncol. 2015 Feb 20;33(6):668-9. doi: 10.1200/JCO.2014.59.6239. Epub 2015 Jan 20. No abstract available.

PMID:
25605859
39.

Estrogen receptor α induces prosurvival autophagy in papillary thyroid cancer via stimulating reactive oxygen species and extracellular signal regulated kinases.

Fan D, Liu SY, van Hasselt CA, Vlantis AC, Ng EK, Zhang H, Dong Y, Ng SK, Chu R, Chan AB, Du J, Wei W, Liu X, Liu Z, Xing M, Chen GG.

J Clin Endocrinol Metab. 2015 Apr;100(4):E561-71. doi: 10.1210/jc.2014-3257. Epub 2015 Jan 16.

PMID:
25594859
40.

BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis.

Li F, Chen G, Sheng C, Gusdon AM, Huang Y, Lv Z, Xu H, Xing M, Qu S.

Endocr Relat Cancer. 2015 Apr;22(2):159-68. doi: 10.1530/ERC-14-0531. Epub 2015 Jan 15.

41.

Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.

Shi X, Liu R, Qu S, Zhu G, Bishop J, Liu X, Sun H, Shan Z, Wang E, Luo Y, Yang X, Zhao J, Du J, El-Naggar AK, Teng W, Xing M.

J Clin Endocrinol Metab. 2015 Apr;100(4):E632-7. doi: 10.1210/jc.2014-3606. Epub 2015 Jan 13.

42.

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Clifton-Bligh R, Tallini G, Holt EH, Sýkorová V.

J Clin Oncol. 2015 Jan 1;33(1):42-50. doi: 10.1200/JCO.2014.56.8253. Epub 2014 Oct 20.

43.

RASAL1 in thyroid cancer: promise from a new friend.

Xing M.

J Clin Endocrinol Metab. 2014 Oct;99(10):3619-21. doi: 10.1210/jc.2014-2645. Epub 2014 Sep 16. No abstract available.

44.

Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.

Liu R, Xing M.

Endocr Relat Cancer. 2014 Oct;21(5):825-30. doi: 10.1530/ERC-14-0359. Epub 2014 Aug 13.

45.

Strong association of high urinary iodine with thyroid nodule and papillary thyroid cancer.

Wang F, Wang Y, Wang L, Wang X, Sun C, Xing M, Zhao W.

Tumour Biol. 2014 Nov;35(11):11375-9. doi: 10.1007/s13277-014-2397-8. Epub 2014 Aug 15.

PMID:
25119588
46.

The sonic hedgehog signaling pathway maintains the cancer stem cell self-renewal of anaplastic thyroid cancer by inducing snail expression.

Heiden KB, Williamson AJ, Doscas ME, Ye J, Wang Y, Liu D, Xing M, Prinz RA, Xu X.

J Clin Endocrinol Metab. 2014 Nov;99(11):E2178-87. doi: 10.1210/jc.2014-1844. Epub 2014 Jul 31.

47.

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.

Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S, Bishop J.

J Clin Oncol. 2014 Sep 1;32(25):2718-26. doi: 10.1200/JCO.2014.55.5094. Epub 2014 Jul 14.

48.

TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.

Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y, Sun H, Shan Z, Teng W, Xing M.

J Clin Endocrinol Metab. 2014 Jun;99(6):E1130-6. doi: 10.1210/jc.2013-4048. Epub 2014 Mar 11.

49.

Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer.

Zhang Z, Liu D, Murugan AK, Liu Z, Xing M.

Endocr Relat Cancer. 2014 Jan 30;21(2):161-73. doi: 10.1530/ERC-13-0399. Print 2014 Apr.

50.

Supplemental Content

Loading ...
Support Center